PPARγ agonists but not PPAR antagonists, as listed in Table 2, have shown inhibitory effects on HSCs and antifibrotic effects in animal models with liver fibrosis and patients with NASH.
No takes yet. Share an insight, caveat, or question.
Ramón Bataller (2005) studied this question.